{"organizations": [], "uuid": "d31fe740f273adfebd25edea311b5f3dd3f49482", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ampio-primary-endpoint-was-change/brief-ampio-primary-endpoint-was-change-in-womac-a-pain-between-baseline-and-week-20-idUSFWN1R80NQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Ampio Primary Endpoint Was Change In Womac A Pain Between Baseline And Week 20​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-26T15:41:00.000+03:00", "replies_count": 0, "uuid": "d31fe740f273adfebd25edea311b5f3dd3f49482"}, "author": "", "url": "https://www.reuters.com/article/brief-ampio-primary-endpoint-was-change/brief-ampio-primary-endpoint-was-change-in-womac-a-pain-between-baseline-and-week-20-idUSFWN1R80NQ", "ord_in_thread": 0, "title": "BRIEF-Ampio Primary Endpoint Was Change In Womac A Pain Between Baseline And Week 20​", "locations": [], "entities": {"persons": [], "locations": [{"name": "womac", "sentiment": "none"}], "organizations": [{"name": "ampio pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 41 PM / Updated 11 minutes ago BRIEF-Ampio Primary Endpoint Was Change In Womac A Pain Between Baseline And Week 20​ Reuters Staff 1 Min Read March 26 (Reuters) - Ampio Pharmaceuticals Inc: * EVIDENCE FOR DELAY OF TOTAL KNEE REPLACEMENT (TKR) FOR PATIENTS WITH SEVERE OSTEOARTHRITIS OF THE KNEE RECEIVING THREE INTRA-ARTICULAR (IA) AMPION™ INJECTIONS * AMPIO PHARMACEUTICALS INC - ‍PRIMARY ENDPOINT WAS CHANGE IN WOMAC A PAIN BETWEEN BASELINE AND WEEK 20​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-26T15:41:00.000+03:00", "crawled": "2018-03-26T15:57:37.016+03:00", "highlightTitle": ""}